ES2049656A1 - New cluster conjugates of drugs with antibodies - for use with e.g. antineoplastic agents, can attach a large number of the cytotoxic drug molecules - Google Patents

New cluster conjugates of drugs with antibodies - for use with e.g. antineoplastic agents, can attach a large number of the cytotoxic drug molecules

Info

Publication number
ES2049656A1
ES2049656A1 ES9202001A ES9202001A ES2049656A1 ES 2049656 A1 ES2049656 A1 ES 2049656A1 ES 9202001 A ES9202001 A ES 9202001A ES 9202001 A ES9202001 A ES 9202001A ES 2049656 A1 ES2049656 A1 ES 2049656A1
Authority
ES
Spain
Prior art keywords
antibodies
drugs
attach
drug molecules
cytotoxic drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES9202001A
Other languages
Spanish (es)
Other versions
ES2049656B1 (en
Inventor
Koppel
Offord
Rose
Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to ES09202001A priority Critical patent/ES2049656B1/en
Publication of ES2049656A1 publication Critical patent/ES2049656A1/en
Application granted granted Critical
Publication of ES2049656B1 publication Critical patent/ES2049656B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a combination that is physiologically acceptable from a drug with formula (I) in which Ac, R, R<1>, X, Z, M, N, P, Q, R, S, Y R<2>, R<3> Y R<4> are determined with details in descriptive memory. It also provides pharmaceutical compositions that contain a combination in the invention and intermediaries to prepare the combinations and a modified drug. It represents significant progress in the field of medicine directed at a concrete objective of enabling fixation of multiple cytotoxic drug molecules to a single antibody molecule, applicable in the treatment of cancer.<IMAGE>
ES09202001A 1992-10-08 1992-10-08 GROUPS OF DRUG CONJUGATES WITH ANTIBODIES. Expired - Lifetime ES2049656B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES09202001A ES2049656B1 (en) 1992-10-08 1992-10-08 GROUPS OF DRUG CONJUGATES WITH ANTIBODIES.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09202001A ES2049656B1 (en) 1992-10-08 1992-10-08 GROUPS OF DRUG CONJUGATES WITH ANTIBODIES.

Publications (2)

Publication Number Publication Date
ES2049656A1 true ES2049656A1 (en) 1994-04-16
ES2049656B1 ES2049656B1 (en) 1994-11-16

Family

ID=8278354

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09202001A Expired - Lifetime ES2049656B1 (en) 1992-10-08 1992-10-08 GROUPS OF DRUG CONJUGATES WITH ANTIBODIES.

Country Status (1)

Country Link
ES (1) ES2049656B1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046722A (en) * 1975-02-04 1977-09-06 G. D. Searle & Co. Limited Immunological materials
US4543211A (en) * 1982-12-24 1985-09-24 Teijin Limited Conjugate having cytotoxicity and process for the preparation thereof
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
EP0326322A1 (en) * 1988-01-27 1989-08-02 Eli Lilly And Company Antibody conjugates
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
EP0354728A2 (en) * 1988-08-08 1990-02-14 Eli Lilly And Company Cytotoxic drug conjugates
EP0368668A2 (en) * 1988-11-10 1990-05-16 Eli Lilly And Company Antibody-drug conjugates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046722A (en) * 1975-02-04 1977-09-06 G. D. Searle & Co. Limited Immunological materials
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US4543211A (en) * 1982-12-24 1985-09-24 Teijin Limited Conjugate having cytotoxicity and process for the preparation thereof
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
EP0326322A1 (en) * 1988-01-27 1989-08-02 Eli Lilly And Company Antibody conjugates
EP0354728A2 (en) * 1988-08-08 1990-02-14 Eli Lilly And Company Cytotoxic drug conjugates
US5006652A (en) * 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
EP0368668A2 (en) * 1988-11-10 1990-05-16 Eli Lilly And Company Antibody-drug conjugates

Also Published As

Publication number Publication date
ES2049656B1 (en) 1994-11-16

Similar Documents

Publication Publication Date Title
HUP0003323A2 (en) Pharmaceutical formulations containing voriconazole
HUP9802339A2 (en) Pharmaceutical formulations containing darifenacin
BG101118A (en) Therapeutical compounds
HUP0002454A2 (en) Targeted therapeutic delivery of vitamin d compounds
ATE235895T1 (en) DRUG DELIVERY SYSTEM CONTAINING A HARD-PACKED, SOLID DRUG BASE
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
HUP0300421A2 (en) Method of treatment using ligand-immunogen conjugates
FR2681862B1 (en) NOVELS (BENZOCYCLOALKYL) ALKYLAMINES, THEIR PREPARATION PROCESS, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
BR0106851A (en) Conjugate mix, pharmaceutical composition, method of treating insulin deficiency in an individual in need of such treatment and process for synthesizing a conjugate mix
IT1245890B (en) PHARMACEUTICAL FORMULATIONS FOR ORAL USE GASTRORESANTS CONTAINING BILE ACIDS.
RU94028670A (en) Immunopotentiating agents, methods of treatment of immunodeficient mammalian, viral infections and cancer in mammalian also
YU35102A (en) Heterocyclo-alkylsulfonyl pyrazole derivatives as anti- inflammatory/analgesic agents
FR2375867A1 (en) MEDICINE BASED ON DEHYDRO-OLIGOPEPTIDES INTENDED FOR THE RESOLUTION OF A TUMOR OR TISSUE
IE940341L (en) Anti-atherosclerotic diaryl compound
AR043071A1 (en) USE OF MACROLIDES FOR THE TREATMENT OF CANCER AND MACULAR DEGENERATION AND A PHARMACEUTICAL COMPOSITION
DE69824313D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SIBUTRAMINE AND ORLISTAT
TR199801614T2 (en) Peptide derivatives
DK0387821T3 (en) 2-Alkyl-4-arylmethylquinolines, their uses and drugs prepared therewith
HUP0004331A3 (en) Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer&#39;s disease and combined pharmaceutical compositions containing it
ES2049656A1 (en) New cluster conjugates of drugs with antibodies - for use with e.g. antineoplastic agents, can attach a large number of the cytotoxic drug molecules
RU94002476A (en) MEDICINE
GEP20043377B (en) Pharmaceutical Complex
ATE28566T1 (en) CELL-TOXIC MEDICINAL PRODUCT CONTAINING AT LEAST AN IMMUNOTOXIN AND AN AMINE.
ES2107174T3 (en) DERIVED FROM ETHOPOSIDE, ITS PREPARATION PROCEDURE, ITS USE AS A MEDICINAL PRODUCT AND ITS USE FOR THE PREPARATION OF A MEDICINE INTENDED FOR ANTI-CANCER TREATMENT.
ZA200600165B (en) Amino acid diamides in non alpha position useful as adjuvants for the administration of active biological agents